SurgiMab products
Tumor-Specific Antibody
SGM-101, currently in Phase III for the delineation of primary and recurrent tumor and metastases in patients undergoing surgery for colorectal cancer, is a tumor-specific antibody conjugated to a near-infrared fluorochrome. It selectively binds a specific marker overexpressed in gastrointestinal and other tumors.
SurgiMab - Intraoperative Detection Technology of Tumors
SurgiMab’s tumor-targeting fluorescent molecules enable real time visualization of tumor margins, tumor spread and micro-tumors which are invisible to the naked eye. As opposed to an indiscriminate contrast agent, this ability to specifically highlight malignant tissue during a procedure opens up a broad market in both surgical tumor resection (FluorescenceGuided Surgery) and potentially also in cancer screening.
Ovarian Cancer Specific Antibody
SGM-201 is a preclinical stage product based on the same technique that targets ovarian cancer. Both allow surgeons to visualize tumors in real-time with a near-infrared camera, helping them to perform more radical cytoreductive surgery, thus automatically improving surgical outcomes.